<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074373</url>
  </required_header>
  <id_info>
    <org_study_id>09-0289</org_study_id>
    <nct_id>NCT00074373</nct_id>
  </id_info>
  <brief_title>The Research Registry for Neonatal Lupus</brief_title>
  <official_title>The Research Registry for Neonatal Lupus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women with lupus and other related disorders produce certain antibodies in the blood. Some
      women have these antibodies even if they have not yet developed symptoms of lupus or
      Sjogren's syndrome. When these women become pregnant, they may pass the antibodies to their
      infants. The infants may then develop a disease called neonatal lupus. The symptoms of
      neonatal lupus include an abnormally slow heart beat (heart block) and a skin rash. This
      registry collects information on women and infants affected by neonatal lupus as well as
      other family members who may be healthy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neonatal lupus is a disease seen in babies born to mothers who have antibodies to SSA/Ro
      and/or SSB/La proteins. The mother may have systemic lupus erythematosus, Sjogren's syndrome,
      or be otherwise healthy. Heart block and a characteristic skin rash are the primary
      manifestations of neonatal lupus.

      The Research Registry for Neonatal Lupus was initiated in 1994 to help basic scientists and
      clinicians better understand the cause of neonatal lupus and discover a cure. The Research
      Registry is a central repository of patient information, sera, and DNA. The Registry provides
      blood samples (kept anonymous) to scientists studying neonatal lupus. Information from the
      registry forms the basis of family counseling and tracks important data such as recurrence
      rates in subsequent pregnancies and the effects of treatments. The Research Registry also
      serves as an educational resource for women who are eager to learn about this disease.

      Women with a child affected by neonatal lupus may enroll in the Registry. Women can be self
      referred or referred by their doctors. Siblings of women with a child affected by neonatal
      lupus, fathers and maternal grandparents of children with neonatal lupus, and unaffected
      siblings of a child with neonatal lupus are also invited to participate in this study. All
      information on the mother and her family is confidential; only nonidentifying information
      will be provided to researchers. Women interested in the registry will be sent articles and
      educational materials about neonatal lupus, a consent form for the Registry, and an
      enrollment questionnaire. Participants will be asked to sign a medical records release form.
      Participants will also be asked to donate a blood sample for antibody testing and DNA
      isolation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 1994</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>means of curing and/or preventing neonatal lupus</measure>
    <time_frame>ongoing</time_frame>
    <description>means of curing and/or preventing neonatal lupus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>identification of pathogenesis of neonatal lupus</measure>
    <time_frame>ongoing</time_frame>
    <description>identification of pathogenesis of neonatal lupus</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Neonatal Lupus</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Sjogren's Syndrome</condition>
  <condition>Congenital Heart Block</condition>
  <arm_group>
    <arm_group_label>human beings</arm_group_label>
    <description>human beings of all sexes, ages, and health statuses</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention; observational</intervention_name>
    <arm_group_label>human beings</arm_group_label>
    <other_name>The study is observational</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with a child affected by neonatal lupus, children affected by neonatal lupus,
        siblings of children affected by neonatal lupus, siblings of women with a child affected by
        neonatal lupus, fathers and maternal grandparents of children with neonatal lupus, and
        unaffected people to serve as controls are invited to participate in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mother with antibodies to SSA/Ro, SSB/La, or ribonucleoproteins (RNP) OR Child of
             mother with such antibodies who has neonatal lupus (congenital heart block, transient
             skin rash, and/or hepatic or hematologic manifestations) OR Father of neonatal
             lupus-affected child OR Maternal grandparents of neonatal lupus-affected child OR
             Maternal aunts and uncles of neonatal lupus-affected OR Unaffected siblings of
             neonatal lupus-affected child
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill P. Buyon, MD</last_name>
    <role>Study Director</role>
    <affiliation>NYU Medical Center, NYU School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zoey Smith</last_name>
    <phone>212-263-0743</phone>
    <email>zoey.smith@nyumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jill Buyon, M.D.</last_name>
    <phone>212-263-0746</phone>
    <email>jill.buyon@nyumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jill P. Buyon, MD</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoey Smith</last_name>
      <phone>212-263-0743</phone>
      <email>zoey.smith@nyumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Jill Buyon, M.D.</last_name>
      <phone>212-263-0746</phone>
      <email>jill.buyon@nyumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jill P. Buyon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://neonatallupus.com/</url>
    <description>Research Registry for Neonatal Lupus Website</description>
  </link>
  <link>
    <url>https://www.facebook.com/pages/Research-Registry-For-Neonatal-Lupus/212655652139338</url>
    <description>Research Registry for Neonatal Lupus Facebook Page</description>
  </link>
  <reference>
    <citation>Buyon JP, Clancy RM. Neonatal lupus: review of proposed pathogenesis and clinical data from the US-based Research Registry for Neonatal Lupus. Autoimmunity. 2003 Feb;36(1):41-50. Review.</citation>
    <PMID>12765470</PMID>
  </reference>
  <reference>
    <citation>Solomon DG, Rupel A, Buyon JP. Birth order, gender and recurrence rate in autoantibody-associated congenital heart block: implications for pathogenesis and family counseling. Lupus. 2003;12(8):646-7. Erratum in: Lupus. 2003;12(10):801.</citation>
    <PMID>12945727</PMID>
  </reference>
  <reference>
    <citation>Askanase AD, Miranda-Carus ME, Tang X, Katholi M, Buyon JP. The presence of IgG antibodies reactive with components of the SSA/Ro-SSB/La complex in human breast milk: implications in neonatal lupus. Arthritis Rheum. 2002 Jan;46(1):269-71.</citation>
    <PMID>11817601</PMID>
  </reference>
  <reference>
    <citation>Askanase AD, Friedman DM, Copel J, Dische MR, Dubin A, Starc TJ, Katholi MC, Buyon JP. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus. 2002;11(3):145-51.</citation>
    <PMID>11999879</PMID>
  </reference>
  <reference>
    <citation>Martin V, Lee LA, Askanase AD, Katholi M, Buyon JP. Long-term followup of children with neonatal lupus and their unaffected siblings. Arthritis Rheum. 2002 Sep;46(9):2377-83.</citation>
    <PMID>12355485</PMID>
  </reference>
  <reference>
    <citation>Neiman AR, Lee LA, Weston WL, Buyon JP. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr. 2000 Nov;137(5):674-80.</citation>
    <PMID>11060534</PMID>
  </reference>
  <reference>
    <citation>Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, Lee LA, Provost TT, Reichlin M, Rider L, Rupel A, Saleeb S, Weston WL, Skovron ML. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998 Jun;31(7):1658-66.</citation>
    <PMID>9626848</PMID>
  </reference>
  <reference>
    <citation>Clancy RM, Buyon JP. Autoimmune-associated congenital heart block: dissecting the cascade from immunologic insult to relentless fibrosis. Anat Rec A Discov Mol Cell Evol Biol. 2004 Oct;280(2):1027-35. Review.</citation>
    <PMID>15368347</PMID>
  </reference>
  <reference>
    <citation>Clancy RM, Buyon JP. More to death than dying: apoptosis in the pathogenesis of SSA/Ro-SSB/La-associated congenital heart block. Rheum Dis Clin North Am. 2004 Aug;30(3):589-602, x. Review.</citation>
    <PMID>15261343</PMID>
  </reference>
  <reference>
    <citation>Clancy RM, Kapur RP, Molad Y, Askanase AD, Buyon JP. Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum. 2004 Jan;50(1):173-82.</citation>
    <PMID>14730614</PMID>
  </reference>
  <reference>
    <citation>Hu K, Qu Y, Yue Y, Boutjdir M. Functional basis of sinus bradycardia in congenital heart block. Circ Res. 2004 Mar 5;94(4):e32-8. Epub 2004 Feb 12.</citation>
    <PMID>14963005</PMID>
  </reference>
  <reference>
    <citation>Clancy RM, Backer CB, Yin X, Chang MW, Cohen SR, Lee LA, Buyon JP. Genetic association of cutaneous neonatal lupus with HLA class II and tumor necrosis factor alpha: implications for pathogenesis. Arthritis Rheum. 2004 Aug;50(8):2598-603.</citation>
    <PMID>15334474</PMID>
  </reference>
  <reference>
    <citation>Gordon P, Khamashta MA, Rosenthal E, Simpson JM, Sharland G, Brucato A, Franceschini F, De Bosschere K, Meheus L, Meroni PL, Hughes GR, Buyon J. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol. 2004 Dec;31(12):2480-7.</citation>
    <PMID>15570655</PMID>
  </reference>
  <reference>
    <citation>Glickstein J, Buyon J, Kim M, Friedman D; PRIDE investigators. The fetal Doppler mechanical PR interval: a validation study. Fetal Diagn Ther. 2004 Jan-Feb;19(1):31-4.</citation>
    <PMID>14646414</PMID>
  </reference>
  <reference>
    <citation>Tran HB, Cavill D, Buyon JP, Gordon TP. Intravenous immunoglobulin and placental transport of anti-Ro/La antibodies: comment on the letter by Kaaja and Julkunen. Arthritis Rheum. 2004 Jan;50(1):337-8; author reply 338.</citation>
    <PMID>14730639</PMID>
  </reference>
  <reference>
    <citation>Buyon JP, Rupel A, Clancy RM. Neonatal lupus syndromes. Lupus. 2004;13(9):705-12. Review.</citation>
    <PMID>15485109</PMID>
  </reference>
  <reference>
    <citation>Neufing PJ, Clancy RM, Jackson MW, Tran HB, Buyon JP, Gordon TP. Exposure and binding of selected immunodominant La/SSB epitopes on human apoptotic cells. Arthritis Rheum. 2005 Dec;52(12):3934-42.</citation>
    <PMID>16320341</PMID>
  </reference>
  <reference>
    <citation>Clancy RM, Buyon JP, Ikeda K, Nozawa K, Argyle DA, Friedman DM, Chan EK. Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. Arthritis Rheum. 2005 Oct;52(10):3079-86.</citation>
    <PMID>16200587</PMID>
  </reference>
  <reference>
    <citation>Buyon JP, Clancy RM. Autoantibody-associated congenital heart block: TGFbeta and the road to scar. Autoimmun Rev. 2005 Jan;4(1):1-7. Review.</citation>
    <PMID>15652772</PMID>
  </reference>
  <reference>
    <citation>Kamel R, Eftekhari P, Clancy R, Buyon JP, Hoebeke J. Autoantibodies against the serotoninergic 5-HT4 receptor and congenital heart block: a reassessment. J Autoimmun. 2005 Aug;25(1):72-6.</citation>
    <PMID>16009533</PMID>
  </reference>
  <reference>
    <citation>Buyon JP, Askanase AD, Kim MY, Copel JA, Friedman DM. Identifying an early marker for congenital heart block: when is a long PR interval too long? Comment on the article by Sonesson et al. Arthritis Rheum. 2005 Apr;52(4):1341-2.</citation>
    <PMID>15818705</PMID>
  </reference>
  <reference>
    <citation>Buyon JP, Clancy RM. Neonatal lupus: basic research and clinical perspectives. Rheum Dis Clin North Am. 2005 May;31(2):299-313, vii. Review.</citation>
    <PMID>15922147</PMID>
  </reference>
  <reference>
    <citation>Stea EA, Routsias JG, Clancy RM, Buyon JP, Moutsopoulos HM, Tzioufas AG. Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum. 2006 Jul;54(7):2228-34.</citation>
    <PMID>16802359</PMID>
  </reference>
  <reference>
    <citation>Askanase AD, Iloh I, Buyon JP. Hypothyroidism and antithyroglobulin and antithyroperoxidase antibodies in the pathogenesis of autoimmune associated congenital heart block. J Rheumatol. 2006 Oct;33(10):2099.</citation>
    <PMID>17014028</PMID>
  </reference>
  <reference>
    <citation>Bachmann MP, Bartsch H, Gross JK, Maier SM, Gross TF, Workman JL, James JA, Farris AD, Jung B, Franke C, Conrad K, Schmitz M, Büttner C, Buyon JP, Semsei I, Harley JB, Rieber EP. Autoimmunity as a result of escape from RNA surveillance. J Immunol. 2006 Aug 1;177(3):1698-707.</citation>
    <PMID>16849479</PMID>
  </reference>
  <reference>
    <citation>Clancy RM, Neufing PJ, Zheng P, O'Mahony M, Nimmerjahn F, Gordon TP, Buyon JP. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest. 2006 Sep;116(9):2413-22. Epub 2006 Aug 10.</citation>
    <PMID>16906225</PMID>
  </reference>
  <reference>
    <citation>Clancy RM, Zheng P, O'Mahony M, Izmirly P, Zavadil J, Gardner L, Buyon JP. Role of hypoxia and cAMP in the transdifferentiation of human fetal cardiac fibroblasts: implications for progression to scarring in autoimmune-associated congenital heart block. Arthritis Rheum. 2007 Dec;56(12):4120-31.</citation>
    <PMID>18050204</PMID>
  </reference>
  <reference>
    <citation>Izmirly PM, Rivera TL, Buyon JP. Neonatal lupus syndromes. Rheum Dis Clin North Am. 2007 May;33(2):267-85, vi. Review.</citation>
    <PMID>17499707</PMID>
  </reference>
  <reference>
    <citation>Friedman DM, Rupel A, Buyon JP. Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus. Curr Rheumatol Rep. 2007 May;9(2):101-8. Review.</citation>
    <PMID>17502039</PMID>
  </reference>
  <reference>
    <citation>Rivera TL, Izmirly PM, Birnbaum BK, Byrne P, Brauth JB, Katholi M, Kim MY, Fischer J, Clancy RM, Buyon JP. Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis. 2009 Jun;68(6):828-35. doi: 10.1136/ard.2008.088054. Epub 2008 Jul 14.</citation>
    <PMID>18625627</PMID>
  </reference>
  <reference>
    <citation>Strandberg L, Winqvist O, Sonesson SE, Mohseni S, Salomonsson S, Bremme K, Buyon JP, Julkunen H, Wahren-Herlenius M. Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. Clin Exp Immunol. 2008 Oct;154(1):30-7. doi: 10.1111/j.1365-2249.2008.03732.x. Epub 2008 Aug 22.</citation>
    <PMID>18727629</PMID>
  </reference>
  <reference>
    <citation>Buyon JP, Brucato A, Friedman DM. What's in a name? Ann Rheum Dis. 2008 May;67(5):732; discussion 732. doi: 10.1136/ard.2007.082693.</citation>
    <PMID>18408119</PMID>
  </reference>
  <reference>
    <citation>Buyon JP, Clancy RM. Dying right to live longer: positing apoptosis as a link between maternal autoantibodies and congenital heart block. Lupus. 2008 Feb;17(2):86-90. doi: 10.1177/0961203307085115. Review.</citation>
    <PMID>18250129</PMID>
  </reference>
  <reference>
    <citation>Niewold TB, Rivera TL, Buyon JP, Crow MK. Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum. 2008 Feb;58(2):541-6. doi: 10.1002/art.23191.</citation>
    <PMID>18240214</PMID>
  </reference>
  <reference>
    <citation>Friedman DM, Kim MY, Copel JA, Davis C, Phoon CK, Glickstein JS, Buyon JP; PRIDE Investigators. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation. 2008 Jan 29;117(4):485-93. doi: 10.1161/CIRCULATIONAHA.107.707661. Epub 2008 Jan 14.</citation>
    <PMID>18195175</PMID>
  </reference>
  <reference>
    <citation>Llanos C, Izmirly PM, Katholi M, Clancy RM, Friedman DM, Kim MY, Buyon JP. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum. 2009 Oct;60(10):3091-7. doi: 10.1002/art.24768.</citation>
    <PMID>19790064</PMID>
  </reference>
  <reference>
    <citation>Buyon JP, Clancy RM, Friedman DM. Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal / foetal dyad at risk. J Intern Med. 2009 Jun;265(6):653-62. doi: 10.1111/j.1365-2796.2009.02100.x. Review.</citation>
    <PMID>19493059</PMID>
  </reference>
  <reference>
    <citation>Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol. 2009 Mar;5(3):139-48. doi: 10.1038/ncprheum1018. Review.</citation>
    <PMID>19252519</PMID>
  </reference>
  <reference>
    <citation>Friedman DM, Kim MY, Copel JA, Llanos C, Davis C, Buyon JP. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol. 2009 Apr 15;103(8):1102-6. doi: 10.1016/j.amjcard.2008.12.027. Epub 2009 Mar 4.</citation>
    <PMID>19361597</PMID>
  </reference>
  <reference>
    <citation>Llanos C, Chan EK, Li S, Abadal GX, Izmirly P, Byrne C, Clancy RM, Buyon JP. Antibody reactivity to alpha-enolase in mothers of children with congenital heart block. J Rheumatol. 2009 Mar;36(3):565-9. doi: 10.3899/jrheum.080860. Epub 2009 Feb 4.</citation>
    <PMID>19208599</PMID>
  </reference>
  <reference>
    <citation>Buyon JP. Updates on lupus and pregnancy. Bull NYU Hosp Jt Dis. 2009;67(3):271-5. Review.</citation>
    <PMID>19852749</PMID>
  </reference>
  <reference>
    <citation>Briassouli P, Komissarova EV, Clancy RM, Buyon JP. Role of the urokinase plasminogen activator receptor in mediating impaired efferocytosis of anti-SSA/Ro-bound apoptotic cardiocytes: Implications in the pathogenesis of congenital heart block. Circ Res. 2010 Aug 6;107(3):374-87. doi: 10.1161/CIRCRESAHA.109.213629. Epub 2010 Jun 17.</citation>
    <PMID>20558828</PMID>
  </reference>
  <reference>
    <citation>Clancy RM, Alvarez D, Komissarova E, Barrat FJ, Swartz J, Buyon JP. Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block. J Immunol. 2010 Feb 15;184(4):2148-55. doi: 10.4049/jimmunol.0902248. Epub 2010 Jan 20.</citation>
    <PMID>20089705</PMID>
  </reference>
  <reference>
    <citation>Clancy RM, Marion MC, Kaufman KM, Ramos PS, Adler A; International Consortium on Systemic Lupus Erythematosus Genetics, Harley JB, Langefeld CD, Buyon JP. Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus. Arthritis Rheum. 2010 Nov;62(11):3415-24. doi: 10.1002/art.27658.</citation>
    <PMID>20662065</PMID>
  </reference>
  <reference>
    <citation>Askanase AD, Izmirly PM, Katholi M, Mumtaz J, Buyon JP. Frequency of neuro-psychiatric dysfunction in anti-SSA/SSB exposed children with and without neonatal lupus. Lupus. 2010 Mar;19(3):300-6. doi: 10.1177/0961203309354542. Epub 2009 Dec 14.</citation>
    <PMID>20008445</PMID>
  </reference>
  <reference>
    <citation>Friedman DM, Llanos C, Izmirly PM, Brock B, Byron J, Copel J, Cummiskey K, Dooley MA, Foley J, Graves C, Hendershott C, Kates R, Komissarova EV, Miller M, Paré E, Phoon CK, Prosen T, Reisner D, Ruderman E, Samuels P, Yu JK, Kim MY, Buyon JP. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum. 2010 Apr;62(4):1138-46. doi: 10.1002/art.27308.</citation>
    <PMID>20391423</PMID>
  </reference>
  <reference>
    <citation>Izmirly PM, Llanos C, Lee LA, Askanase A, Kim MY, Buyon JP. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum. 2010 Apr;62(4):1153-7. doi: 10.1002/art.27333.</citation>
    <PMID>20131261</PMID>
  </reference>
  <reference>
    <citation>Karnabi E, Qu Y, Wadgaonkar R, Mancarella S, Yue Y, Chahine M, Clancy RM, Buyon JP, Boutjdir M. Congenital heart block: identification of autoantibody binding site on the extracellular loop (domain I, S5-S6) of alpha(1D) L-type Ca channel. J Autoimmun. 2010 Mar;34(2):80-6. doi: 10.1016/j.jaut.2009.06.005. Epub 2009 Jul 28.</citation>
    <PMID>19640679</PMID>
  </reference>
  <reference>
    <citation>Reynolds HR, Buyon J, Kim M, Rivera TL, Izmirly P, Tunick P, Clancy RM. Association of plasma soluble E-selectin and adiponectin with carotid plaque in patients with systemic lupus erythematosus. Atherosclerosis. 2010 Jun;210(2):569-74. doi: 10.1016/j.atherosclerosis.2009.12.007. Epub 2009 Dec 16.</citation>
    <PMID>20044088</PMID>
  </reference>
  <reference>
    <citation>Saxena A, McDonnell E, Ramos PS, Sajuthi S, Marion MC, Langefeld CD, Buyon JP, Clancy RM. Preferential transmission of genetic risk variants of candidate loci at 6p21 from asymptomatic grandparents to mothers of children with neonatal lupus. Arthritis Rheum. 2012 Mar;64(3):931-9. doi: 10.1002/art.33366.</citation>
    <PMID>22031281</PMID>
  </reference>
  <reference>
    <citation>Izmirly PM, Saxena A, Kim MY, Wang D, Sahl SK, Llanos C, Friedman D, Buyon JP. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation. 2011 Nov 1;124(18):1927-35. doi: 10.1161/CIRCULATIONAHA.111.033894. Epub 2011 Oct 3.</citation>
    <PMID>21969015</PMID>
  </reference>
  <reference>
    <citation>Briassouli P, Rifkin D, Clancy RM, Buyon JP. Binding of anti-SSA antibodies to apoptotic fetal cardiocytes stimulates urokinase plasminogen activator (uPA)/uPA receptor-dependent activation of TGF-β and potentiates fibrosis. J Immunol. 2011 Nov 15;187(10):5392-401. doi: 10.4049/jimmunol.1101288. Epub 2011 Oct 17.</citation>
    <PMID>22013113</PMID>
  </reference>
  <reference>
    <citation>Routsias JG, Kyriakidis NC, Friedman DM, Llanos C, Clancy R, Moutsopoulos HM, Buyon J, Tzioufas AG. Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block. Arthritis Rheum. 2011 Sep;63(9):2783-9. doi: 10.1002/art.30464.</citation>
    <PMID>21618202</PMID>
  </reference>
  <reference>
    <citation>Alvarez D, Briassouli P, Clancy RM, Zavadil J, Reed JH, Abellar RG, Halushka M, Fox-Talbot K, Barrat FJ, Buyon JP. A novel role of endothelin-1 in linking Toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block. J Biol Chem. 2011 Sep 2;286(35):30444-54. doi: 10.1074/jbc.M111.263657. Epub 2011 Jul 5.</citation>
    <PMID>21730058</PMID>
  </reference>
  <reference>
    <citation>Reed JH, Clancy RM, Purcell AW, Kim MY, Gordon TP, Buyon JP. β2-glycoprotein I and protection from anti-SSA/Ro60-associated cardiac manifestations of neonatal lupus. J Immunol. 2011 Jul 1;187(1):520-6. doi: 10.4049/jimmunol.1100122. Epub 2011 May 20.</citation>
    <PMID>21602492</PMID>
  </reference>
  <reference>
    <citation>Reed JH, Clancy RM, Lee KH, Saxena A, Izmirly PM, Buyon JP. Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus. Arthritis Care Res (Hoboken). 2012 Sep;64(9):1373-81. doi: 10.1002/acr.21704.</citation>
    <PMID>22511615</PMID>
  </reference>
  <reference>
    <citation>Cherian TS, Kariuki SN, Franek BS, Buyon JP, Clancy RM, Niewold TB. Brief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus. Arthritis Rheum. 2012 Oct;64(10):3383-7. doi: 10.1002/art.34571.</citation>
    <PMID>22674082</PMID>
  </reference>
  <reference>
    <citation>Izmirly PM, Buyon JP, Saxena A. Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease. Curr Opin Rheumatol. 2012 Sep;24(5):466-72. doi: 10.1097/BOR.0b013e328356226b. Review.</citation>
    <PMID>22832822</PMID>
  </reference>
  <reference>
    <citation>Ramos PS, Marion MC, Langefeld CD; International Consortium on Systemic Lupus Erythematosus Genetics, Buyon JP, Clancy RM. Brief report: enrichment of associations in genes with fibrosis, apoptosis, and innate immunity functions with cardiac manifestations of neonatal lupus. Arthritis Rheum. 2012 Dec;64(12):4060-5. doi: 10.1002/art.34663.</citation>
    <PMID>22886516</PMID>
  </reference>
  <reference>
    <citation>Reed JH, Jain M, Lee K, Kandimalla ER, Faridi MH, Buyon JP, Gupta V, Clancy RM. Complement receptor 3 influences toll-like receptor 7/8-dependent inflammation: implications for autoimmune diseases characterized by antibody reactivity to ribonucleoproteins. J Biol Chem. 2013 Mar 29;288(13):9077-83. doi: 10.1074/jbc.M112.403303. Epub 2013 Feb 5.</citation>
    <PMID>23386618</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2003</study_first_submitted>
  <study_first_submitted_qc>December 11, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2003</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-SSA/Ro Antibodies</keyword>
  <keyword>Anti-SSB/La Antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Heart Block</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

